1-ethyl-cyclohexanecarboxylic acid amide | 1124-97-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-ethyl-cyclohexanecarboxylic acid amide
• 英文别名: 1-Aethyl-cyclohexancarbonsaeure-amid；1-Ethyl-1-cyclohexyl-carboxamide；1-Aethyl-cyclohexan-carbonsaeure-(1)-amid；1-Ethylcyclohexanecarboxamide；1-ethylcyclohexane-1-carboxamide
• CAS: 1124-97-6
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: ZOJNANYILVFQBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethyl-cyclohexanecarboxylic acid amide 在 氢氧化钾 、 次溴酸钾 作用下， 生成 1-氨基-1-乙基环己烷
  参考文献：
  名称：

  The Synthesis of Some Teritary Carbinamines as Vasopressor Agents

  摘要：

  DOI：

  10.1021/ja01098a033
• 作为产物：
  描述：

  环己基苯基甲酮 在 sodium amide 、 甲苯 作用下， 生成 1-ethyl-cyclohexanecarboxylic acid amide
  参考文献：
  名称：

  The Synthesis of Some Teritary Carbinamines as Vasopressor Agents

  摘要：

  DOI：

  10.1021/ja01098a033

文献信息

• DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090029977A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , X and n are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及公式（I）中R1、R2、X和n的化合物，其在说明书中被定义为5-HT2a和D3受体的双调节剂，它们的制备、含有它们的药物组合物以及它们用于治疗精神病性障碍以及其他疾病，如抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍。
• Pharmaceutically active cyclohexyl compounds and their preparation
  申请人：Labaz

  公开号：US04283420A1

  公开（公告）日：1981-08-11

  The chemical compounds of the invention are useful as the active compound in drugs because of their anticonvulsant and/or antianoxic activity. They have the general formula ##STR1## wherein Z is a hydroxyl group; a group--OM wherein M is an alkali metal atom or an equivalent atom fraction of an alkaline-earth metal or an amino group such as --NH.sub.2, and R is a linear or branched alkyl group containing from 1 to 9 carbon atoms, and optionally substituted by one or more halogen atoms; a linear or branched alkenyl or alkynyl, alkoxyalkyl, or acylalkyl group containing from 2 to 9 carbon atoms and optionally substituted by one or more halogen atoms; an aryl or arylalkyl or aryloxyalkyl group comprising at least one aromatic radical and an alkyl chain having from 1 to 4 carbon atoms.

  本发明的化合物可作为药物中的活性化合物，因为它们具有抗惊厥和/或抗缺氧活性。它们具有以下一般式：其中Z为羟基；一个基团-OM，其中M是碱金属原子或碱土金属的等效原子分数，或者是氨基团，如-NH2；R是含有1至9个碳原子的直链或支链烷基基团，可选地被一个或多个卤素原子取代；一种含有2至9个碳原子的直链或支链烯烃或炔烃、烷氧基烷基或酰基烷基基团，可选地被一个或多个卤素原子取代；一种芳基或芳基烷基或芳氧基烷基基团，包含至少一个芳香基团和一个含有1至4个碳原子的烷基链。
• 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES
  申请人：Aspnes Gary E.

  公开号：US20100204119A1

  公开（公告）日：2010-08-12

  The invention provides compounds of Formula (I), wherein R 1 , R 2a , R 2b , R 3 , m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.

  本发明提供了式（I）的化合物，其中R1，R2a，R2b，R3，m和A如本文所定义，以及它们的组合物和通过给予本发明的化合物和/或组合物来抑制二酰甘油O-酰基转移酶1（DGAT-1）酶而治疗受DGAT-1调节的疾病，情况或紊乱的方法。
• OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH
  申请人：Nantermet Philippe G.

  公开号：US20130012526A1

  公开（公告）日：2013-01-10

  The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的调节剂和FAAH成像剂。本发明还涉及包含这些化合物作为活性成分的药物配方以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后遗神经痛、肌骨疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Fluoroamide-Directed Regiodivergent C-Alkylation of Nitroalkanes
  作者：Zhibin Du、Shiwen Liu、Yuke Li、Junjie Peng、Yanji Sun、Yanshan Song、Yuxuan Liu、Xiaojun Zeng

  DOI：10.1021/acs.orglett.3c01297

  日期：2023.6.30

  Herein, by exploiting different activation modes of fluoroamides, we achieved α- and δ-C(sp3)–H alkylation of nitroalkanes with switchable regioselectivity. Cu catalysis enabled the interception of a distal C-centered radical by a N-centered radical to couple nitroalkanes and unactivated δ-C–H bonds. In addition, imines generated in situ by fluoroamides were trapped by nitroalkanes to realize the α-C–H

  在此，通过利用氟酰胺的不同活化模式，我们实现了具有可切换区域选择性的硝基烷烃的α-和δ-C(sp 3 )–H烷基化。Cu 催化作用使得以 N 为中心的自由基拦截远端以 C 为中心的自由基，从而偶联硝基烷烃和未活化的 δ-C-H 键。此外，氟酰胺原位生成的亚胺被硝基烷烃捕获，实现酰胺的α-C-H烷基化。这两种可扩展的协议都具有广泛的底物范围和良好的官能团耐受性。